Preliminary findings from our “long COVID” survey with M3 panel members

Last June we surveyed 295 members of our panel, with respondents across Germany, France, UK, Italy, Spain, and the United States. All respondents had previously tested positive with COVID-19.

M3 gained insight into the consequences of contracting the virus, the symptoms that can linger for months afterwards, and the uncertainty of when these symptoms will subside.

The research appears to indicate that having long-term symptoms is not linked to how ill you are when first contracting COVID-19, as people who had mild symptoms at first have long-term problems. 

This presents more challenges to healthcare systems around the world, as they will have to adapt to a new reality where treatment will be needed for patients with long-lasting consequences of COVID-19. This could be in the form of specialist rehabilitation services, or a service that specialises in the specific symptoms the long COVID patient has. 

See the preliminary results of our survey.

Sign up and take part in paid healthcare market research

Share on WhatsApp

Leave a Reply

Join Today

Registration is free and only takes a few clicks

Panel Members

Check your available studies

latest posts

emerging respiratory treatments for lung cancer - cystic fibrosis - robotic navigation - gene-editing nanoparticles

Emerging Respiratory Treatments: Frontiers in Pulmonology

Emerging respiratory medicines and treatments, including robotic navigation and gene-editing nanoparticles, may significantly improve patient outcomes in the future for prevalent pulmonary diseases like lung cancer, cystic fibrosis, and chronic obstructive pulmonary disease.

Paid Studies About Medical Devices | M3 Guide

Real-World Evidence studies collect real-world data to evaluate the safety and performance of medical devices. This M3 Guide reveals how we conduct Real-World Evidence studies, how they contribute to better patient outcomes, and how healthcare professionals can get compensated.